Margoles L, Rio C, Franco-Paredes C

Language: English
References: 24
Page: 110-116
PDF size: 275.16 Kb.

Text Extraction

Leprosy or Hansen’s disease is a chronic mycobacterial infectious disease caused by Mycobacterium leprae and affects mainly peripheral nerves and skin as well as upper respiratory mucosae. This infection is a conjoined bacteriological and immunological disease. Target cells of infection are macrophages, histiocytes in the skin, and the nonmyelinating and myelinating Schwann cells in the peripheral nerves leading to axonal dysfunction and demyelination leading to functional impairment and deformity. Leprosy reactions represent the most important determinant of nerve impairment if untreated and unrecognized. Control of leprosy transmission remains a challenge despite substantial improvements through the use of multidrug therapy in many settings. Most importantly, although many patients have been microbiologically cured through the efforts of the World Health Organization, many are left with significant disability that has recently been estimated to be ~20% of those treated (~15 million individuals) in the last decades. Further efforts are needed to elucidate the epidemiology and risk factors for disability among those with multibacillary forms.

REFERENCES

1. Walker SL, Lockwood DNJ. The clinical and immunological features of leprosy. Br Med Bull 2006;77-78:103-121.

2. World Health Organization. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities 2006-2010. Operational Guidelines. Geneva: World Health Organization; 2006. Contract No.: WHO/CDS/CPE/CEE/2005.53.

3. World Health Organization. Leprosy (Hansen disease). Report by Secretariat. Executive Board, December 16, 2010. Geneva.

4. Rodriguez O. La lucha contra la lepra en México. Rev Fac Med UNAM 2003;46:109-113.

5. Scollard DM. The biology of nerve injury in leprosy. Lepr Rev 2008;79:242-253.

6. Yoder LJ. Management of reactions in Hansen’s Disease. The Star. Carville (Louisiana): Gillis W. Long Hansen’s Disease Program; 1996.

7. World Health Organization. Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec 2008;83:293-300.

8. Panamerican Health Organization. Situation report: leprosy in the Americas, 2007. Available at: http://www.paho.org/English/AD/DPC/CD/lep-sit-reg-2007.pdf

9. Anderson H, Stryjewska B, Boyanton BL, Schwartz MR. Hansen disease in the United States in the 21st century: a review of the literature. Arch Pathol Lab Med 2007;131:982-986.

10. Ooi WW, Moschella SL. Update on leprosy in immigrants in the United States: status in the year 2000. Clin Infect Dis 2001;32:930-937.

11. Franco-Paredes C, Jacob JT, Stryjewska B, Yoder L. Two patients with leprosy and the sudden appearance of inflammation in the skin and new sensory loss. PLoS Negl Trop Dis 2009;3:e425.

12. Britton WJ, Lockwood DNJ. Leprosy. Lancet 2004;363:1209-1219.

13. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobac Dis1966;34:255-273.

14. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev 2006;19:338-381.

15. Boggild AK, Keystone JS, Kain KC. Leprosy: a primer for Canadian physicians. CMAJ 2004;170:71-78.

16. van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, Jadhav RS, et al. The INFIR Cohort Study: investigating prediction, detection, and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in North India. Lepr Rev 2005;76:14-34.

17. van Brakel WH, Nicholls PG, Wilder-Smith EP, Das L, Barkataki P, Lockwood DNJ, et al. Early diagnosis of neuropathy in leprosy comparing diagnostic tests in a large prospective study (the INFIR Cohort Study). PLoS Negl Trop Dis 2008;2:e212.

18. Haslett PA, Roche P, Butlin CR, Macdonald M, Shrestha N, Manandhar R, et al. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J Infect Dis 2005;192:2045-2053.

19. Graham A, Furlong S, Margoles L, Owusu K, Franco-Paredes C. Clinical management of leprosy reactions. Infect Dis Clin Pract 2010;18:235-238.

20. Lockwood DNJ, Lucas SB, Desikan KV, Ebenezer G, Suneetha S, Nicholls P. The histological diagnosis of leprosy type 1 reactions: identification of key variables and an analysis of the process of histological diagnosis. J Clin Pathol 2008;61:595-600.

21. Deps PD, Lockwood DNJ. Leprosy occurring as immune reconstitution syndrome. Trans R Soc Trop Med Hyg 2008;102:966-968.

22. Kahawita IP, Lockwood DNJ. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg 2008;102:329-337.

23. Walker SL, Waters MF, Lockwood DNJ. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 2007;78:197-215.

24. Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, et al. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg 2006;74:868-879.